MedTrace Logo

Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer

NCT05908838 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2023-06-18

No results posted yet for this study

Summary

Research purpose To elucidate the effect mechanism and clinical effective of Modified Banxia Xiexin Decoction in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of Modified Banxia Xiexin Decoction's treatment on gastric cancer

Conditions

  • Gastric Cancer (Diagnosis)

Interventions

DRUG

Modified Banxia Xiexin Decoction

The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.

DRUG

combination chemotherapy with Placebo granules

combination chemotherapy with Placebo granules

Sponsors & Collaborators

  • ShuGuang Hospital

    lead OTHER

Principal Investigators

  • Mingyu Sun, doctor · Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2022-12-01
Completion
2022-12-02

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05908838 on ClinicalTrials.gov